Skip to content

Cryptic Clues On The Latest News

Primary Menu
  • Home
  • Games From The Crypt
  • Gadget Guides
  • Crypto News
  • Social Web
  • Contact Us
  • Home
  • Latest
  • Biogen Cuts Price for Alzheimer’s Drug Aduhelm by Half

Biogen Cuts Price for Alzheimer’s Drug Aduhelm by Half

Mandy Macintyre December 23, 2021 4 min read
161

Biogen Inc. announced the launch of a new drug for Alzheimer’s disease, and managed to slash its price by more than half after an intellectual property dispute with Switzerland-based Novartis AG.
The latest version of Aduhelm – known as BIIB021 or aducanumab in humans – is expected to hit the market at $65,000 per year instead of $130,000 previously.
In October 2017 Biogen sued Swiss pharma giant Novartis over patent infringement; arguing that they were infringing on four patents related to spinal nerve cell death while developing their own humanised antibody-drug fusion treatment.

Novartis said last month that it was “disappointed” but had no plans changing course amid what it believed would be a lengthy legal battle with Biogen. The two companies have been battling each other since April 2016 when Novartis applied for US approval for a similar drug called Luxturna

Biotech stocks saw significant drops following this news due to fears about costly legal battles and negative impacts on profits from sales if their drugs don’t receive FDA approval

Biogen has cut the price of their drug aducanumab by half. The company is hoping that they can get more people to take this drug and help them find a cure for Alzheimer’s disease.

Biogen Inc. BIIB 0.81 percent is halving the price of Aduhelm, a contentious new Alzheimer’s disease medication, in an attempt to resurrect a product launch that has delayed in part due to a backlash over the drug’s pricing.

Biogen said Monday that the price decrease would lower the average annual cost of therapy to $28,200 per patient, down from $56,000 when the medication was authorized in June.

Biogen, whose stock has been dragged down by Aduhelm’s dismal performance, has announced plans to decrease expenses by $500 million, but the specifics are still being worked out.

Aduhelm is the first novel Alzheimer’s disease medication in over two decades, but it’s been used infrequently, owing to health insurance’ reluctance to pay for it.

“Too many patients are not being given the option of Aduhelm owing to cost concerns, and as a result, they are going beyond the point of benefitting from the first medication to target an underlying pathology of Alzheimer’s disease,” stated Michel Vounatsos, CEO of Biogen.

Because of uncertainties regarding the medicine’s efficacy and worries about possible adverse effects, some health insurers, including the Department of Veterans Affairs, have rejected to pay for it. Some institutions have refused to deliver the medicine, which needs monthly infusions by a nurse or other healthcare expert, citing cost as a reason.

Aduhelm is the first Alzheimer’s disease therapy in over two decades.

Jessica Rinaldi/Press Pool photo

The price of Biogen’s initial public offering (IPO) became a sticking point in Aduhelm’s clearance process. Some healthcare experts predicted that the medicine will result in tens of billions of dollars in extra expenditure by Medicare, the federal insurance program for those over 65, which covers the majority of Alzheimer’s patients.

Biogen is waiting for government authorities to decide whether Medicare would cover Aduhelm and other similar treatments in the future, which Biogen highlighted as a reason in the price reduction.

“We believe that our efforts today will make these novel Alzheimer’s medicines more accessible to patients,” Mr. Vounatsos added.

Following a public comment period, a preliminary Medicare coverage decision will be issued in January, followed by a final decision in April.

According to the business, up to 50,000 patients might begin Aduhelm therapy next year provided insurance coverage and other conditions including availability to diagnostic tests are in place.

Biogen is hoping that Aduhelm will be the company’s next big hit.

Generics and newer brand-name medications are putting pressure on sales of the company’s primary multiple sclerosis treatments. In the third quarter, Aduhelm was unable to take up the slack, producing a dismal $300,000 in sales.

Biogen’s stock has been pummeled by Aduhelm’s dormant debut, with the stock ending Friday at $237.43, down 43 percent from a 2021 closing high of $414.71 in June, after Aduhelm’s approval.

Biogen said it expects to reap a large amount of the $500 million cost-cutting reductions in 2022. The firm wouldn’t disclose whether the cost-cutting would entail layoffs, but it did state that part of the savings will be offset by investments in its pipeline and strategic initiatives.

The cost-cutting details will be completed in the following weeks and announced in the first quarter of next year, according to the corporation.

Joseph Walker can be reached at joseph.walker@wsj.com.

Dow Jones & Company, Inc. All Rights Reserved. Copyright 2021 Dow Jones & Company, Inc. 87990cbe856818d5eddac44c7b1cdeb8

Watch This Video-

Biogen Inc. has cut the price for its drug Aducanumab by half. This will reduce the cost of treatment for Alzheimer’s patients in the United Kingdom by about $10,000 a year. Reference: aducanumab cost uk.

Related Tags

  • biogen aducanumab
  • cost of new alzheimer’s drug
  • biogen alzheimer’s drug price
  • new alzheimer’s drug aducanumab
  • aducanumab cost in india

Mandy Macintyre

See author's posts

Continue Reading

Previous: Aging Germany Is Running Out of Workers, Putting Europe’s Largest Economy at Risk
Next: NBA Rumors: 5 Blockbuster Trades We Could See Very Soon

Trending Now

How Moove’s Vehicle Financing Product Works african 105m a2 23m serieskeneokafortechcrunch 1

How Moove’s Vehicle Financing Product Works

March 26, 2023
Finclusion to Use Funds to Transform Into a Bank and Expand to Mozambique and Uganda african group ai 20m preserieskeneokafortechcrunch 2

Finclusion to Use Funds to Transform Into a Bank and Expand to Mozambique and Uganda

March 26, 2023
How Will Finclusion’s Credit-Led Neobank Help Africa? finclusion group ai preserieskeneokafortechcrunch 3

How Will Finclusion’s Credit-Led Neobank Help Africa?

March 26, 2023
InstaDeep is Committed to Using Their AI Products to Make the World a Better Place tunis londonbased ai 100m series serieskeneokafortechcrunch 4

InstaDeep is Committed to Using Their AI Products to Make the World a Better Place

March 26, 2023
The Impact of InstaDeep’s Success on the AI Startup Ecosystem londonbased instadeep ai 100m 7m serieskeneokafortechcrunch 5

The Impact of InstaDeep’s Success on the AI Startup Ecosystem

March 26, 2023
What Stitch’s $21 Million Series A Means for Africa’s Fintech Sector africabased stitch apis serieskeneokafortechcrunch 6

What Stitch’s $21 Million Series A Means for Africa’s Fintech Sector

March 26, 2023

Related Stories

How Moove’s Vehicle Financing Product Works african 105m a2 23m serieskeneokafortechcrunch
12 min read

How Moove’s Vehicle Financing Product Works

March 26, 2023 53
Finclusion to Use Funds to Transform Into a Bank and Expand to Mozambique and Uganda african group ai 20m preserieskeneokafortechcrunch
9 min read

Finclusion to Use Funds to Transform Into a Bank and Expand to Mozambique and Uganda

March 26, 2023 61
How Will Finclusion’s Credit-Led Neobank Help Africa? finclusion group ai preserieskeneokafortechcrunch
9 min read

How Will Finclusion’s Credit-Led Neobank Help Africa?

March 26, 2023 56
InstaDeep is Committed to Using Their AI Products to Make the World a Better Place tunis londonbased ai 100m series serieskeneokafortechcrunch
11 min read

InstaDeep is Committed to Using Their AI Products to Make the World a Better Place

March 26, 2023 59
The Impact of InstaDeep’s Success on the AI Startup Ecosystem londonbased instadeep ai 100m 7m serieskeneokafortechcrunch
9 min read

The Impact of InstaDeep’s Success on the AI Startup Ecosystem

March 26, 2023 60
What Stitch’s $21 Million Series A Means for Africa’s Fintech Sector africabased stitch apis serieskeneokafortechcrunch
10 min read

What Stitch’s $21 Million Series A Means for Africa’s Fintech Sector

March 26, 2023 52

Trending on cryptic News

The Ultimate Guide to AirPods and Android jobandtalent 290m 80k lomastechcrunch 1

The Ultimate Guide to AirPods and Android

October 3, 2022
Free app to see wifi passwords facebook messenger instagram octoberlundentechcrunch 2

Free app to see wifi passwords

October 3, 2022
Crypto com is a safer way to transfer money online web3sloan the society doubledagger 3

Crypto com is a safer way to transfer money online

September 28, 2022
2022 Bitcoin Crash tether ethereum bloxy tetherbrauncoindesk 4

2022 Bitcoin Crash

September 26, 2022
Ethereum vs. Ethereum Classic 5

Ethereum vs. Ethereum Classic

August 16, 2022
  • Contact Us
  • Privacy Policy
  • T & C
  • About The Crew
Cryptic Street © All rights reserved.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT